You have 9 free searches left this month | to do more

obinutuzumab

Obinutuzumab is a drug used to treat Chronic Lymphocytic Leukemia, Follicular Lymphoma, Small Lymphocytic Lymphoma, and other conditions. Obinutuzumab is being actively studied in 97 studies and prior, has been studied in 42.

Top SponsorsTop SitesTop Investigators
Hoffmann-La RocheHospital Universitari Vall d'Hebron; Servicio de HematologiaJonathon Cohen
Genentech, Inc.Samsung Medical CenterJoseph Tuscano
National Cancer Institute (NCI)M D Anderson Cancer CenterMatthew S. Davids, MD
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • Mantle Cell Lymphoma
  • +2 more
  • Madison, Wisconsin
    University of Wisconsin Carbone Cancer Center
2022-03-07
Mar 7, 2022
K
Terminated
  • Primary CNS Lymphoma
  • Stuttgart, Baden-Württemberg, Germany
    Klinikum Stuttgart
2022-01-18
Jan 18, 2022
M
Recruiting
  • Primary Focal Segmental Glomerulosclerosis
  • Obinutuzumab
  • Rochester, Minnesota
    Mayo Clinic in Rochester
2021-12-13
Dec 13, 2021
N
Terminated
  • Leukemia
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-03-11
Mar 11, 2022
I
Not yet recruiting
  • Follicular Lymphoma ( FL)
  • Marginal Zone Lymphoma (MZL)
  • (no location specified)
2022-02-07
Feb 7, 2022
M
Not yet recruiting
  • Membranous Nephropathy
  • Obinutuzumab
  • Bergamo, BG, Italy
  • +1 more
2022-03-11
Mar 11, 2022
S
Active, not recruiting
  • Follicular Lymphoma
  • Basel, Switzerland
  • +5 more
2022-02-24
Feb 24, 2022
U
Recruiting
  • Follicular Lymphoma
  • Chicago, Illinois
    University of Chicago Medical Center
2021-11-12
Nov 12, 2021
D
Recruiting
  • Graft vs. Host Disease
  • Obinutuzumab
  • Placebo
  • Palo Alto, California
  • +4 more
2022-03-23
Mar 23, 2022
O
Completed
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-12-10
Dec 10, 2021
M
Recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2021-11-18
Nov 18, 2021
N
Suspended
  • Follicular Lymphoma
  • +4 more
  • Obinutuzumab
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
D
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Boston, Massachusetts
  • +3 more
2022-01-03
Jan 3, 2022
F
Active, not recruiting
  • Waldenstrom Macroglobulinemia
  • Tours, France
    Project manager
2021-06-28
Jun 28, 2021
M
Active, not recruiting
  • Grade 3a Follicular Lymphoma
  • +9 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-09
Feb 9, 2022
D
Recruiting
  • Chronic Lymphocytic Leukemia (CLL)
  • Stamford, Connecticut
  • +4 more
2021-11-22
Nov 22, 2021
E
Recruiting
  • Grade 1 Follicular Lymphoma
  • +7 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
2021-12-07
Dec 7, 2021
A
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Columbus, Ohio
    Research Site
2022-03-11
Mar 11, 2022
M
Active, not recruiting
  • Ann Arbor Stage II Grade 1 Follicular Lymphoma
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
2022-02-18
Feb 18, 2022
U
Completed
  • Lymphoma, Non-Hodgkin's
  • Obinutuzumab
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-04-11
Apr 11, 2021
M
Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
2022-01-06
Jan 6, 2022